The authors are saddened to report the passing in March 2011 of Thomas Littlejohn, III, MD, esteemed physician, investigator, colleague, and coauthor of posters and publications from the TRINITY study. His contributions to this manuscript were invaluable.
24-Hour Efficacy and Safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy
Version of Record online: 28 OCT 2011
© 2011 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 13, Issue 12, pages 873–880, December 2011
How to Cite
Izzo Jr, J. L., Chrysant, S. G., Kereiakes, D. J., Littlejohn III, T., Oparil, S., Melino, M., Lee, J., Fernandez, V. and Heyrman, R. (2011), 24-Hour Efficacy and Safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy. The Journal of Clinical Hypertension, 13: 873–880. doi: 10.1111/j.1751-7176.2011.00544.x
- Issue online: 5 DEC 2011
- Version of Record online: 28 OCT 2011
- Manuscript received May 25, 2011; Revised: August 5, 2011; Accepted: August 11, 2011
J Clin Hypertens (Greenwich). 2011;13:873–880. ©2011 Wiley Periodicals, Inc.
This 12-week, multicenter, randomized, double-blinded, 4-arm study in 440 patients with moderate to severe hypertension compared ambulatory blood pressure (ABP) responses with a triple-combination regimen (olmesartan medoxomil [OM] 40 mg, amlodipine besylate [AML] 10 mg, and hydrochlorothiazide [HCTZ] 25 mg) and its component dual-combination regimens at similar doses. At week 12, the triple combination resulted in a greater reduction in mean 24-hour systolic and diastolic blood pressure (−30.3/−18.0 mm Hg) compared with the 3 dual-combination regimens (OM 40 mg/AML 10 mg: −23.5/−13.9, OM 40 mg/HCTZ 25 mg: −23.9/−14.5, and AML 10 mg/HCTZ 25 mg: −18.5 mm Hg/−10.7 mm Hg; P<.0001 each). Greater efficacy was also found during daytime and nighttime hours and during the last 6, 4, or 2 hours of the dosing interval. The authors conclude that the triple combination of OM 40 mg/AML 10 mg/HCTZ 25 mg demonstrated superior efficacy and sustained reductions in ABP compared with its dual-combination components.